Cue Biopharma, INC 8-K filings

Cue Biopharma, Inc. has appointed James Ahlers as its new Chief Financial Officer, effective July 30, 2026, bringing extensive experience in biopharmaceutical finance.

Cue Biopharma announced a $50 million private placement of common stock and pre-funded warrants to accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to fund clinical development.

Cue Biopharma's stockholders approved the 2026 Stock Incentive Plan and the issuance of shares related to a licensing deal at a special meeting on June 1, 2026.

Cue Biopharma has announced significant changes to its Board of Directors and executive leadership, including the appointment of a new Chief Legal & Compliance Officer and Principal Accounting Officer, and the addition of two new directors.

Cue Biopharma announced first quarter 2026 financial results, highlighting strategic pipeline enhancements, a significant private placement, and leadership changes.

Cue Biopharma announced a 1-for-30 reverse stock split effective April 23, 2026, to regain compliance with Nasdaq's minimum bid price requirement.

Cue Biopharma's stockholders voted on director elections, auditor ratification, executive compensation, and a proposed reverse stock split at their annual meeting.

Cue Biopharma has achieved a preclinical milestone in its collaboration with Boehringer Ingelheim, triggering a $7.5 million payment following the selection of a lead optimization compound.

Cue Biopharma, Inc. announced the resignation of CEO Usman Azam and the appointment of Lucinda Warren as Interim President and Chief Executive Officer.

Cue Biopharma announced improved financial results for Q4 and full year 2025, driven by a new strategic collaboration and progress in its lead autoimmune asset, CUE-401.

Cue Biopharma, Inc. announced the appointment of Lucinda Warren, previously Chief Business Officer, as its new Chief Financial and Business Officer, effective February 9, 2026.

Cue Biopharma announced the pricing of an underwritten public offering of common stock and warrants, expected to raise approximately $8.9 million in net proceeds, extending its cash runway into Q1 2027.

Cue Biopharma, Inc. announced the public availability of its updated corporate presentation on its website.

Cue Biopharma's Chief Medical Officer, Matteo Levisetti, will depart on November 28, 2025, receiving a severance package including a $556,837.60 cash payment.

Cue Biopharma reported Q3 2025 financial results, highlighted a new strategic collaboration with ImmunoScape, and announced a leadership transition.

Cue Biopharma enters a significant collaboration with ImmunoScape for its CUE-100 Series, securing $15M, 40% equity, and royalties.

Cue Biopharma, Inc. announced the appointment of Usman Azam as its new President and Chief Executive Officer, effective September 29, 2025, succeeding Daniel R. Passeri.

Cue Biopharma announced positive Q2 2025 financial results, significant clinical advancements for CUE-101, and a new strategic collaboration with Boehringer Ingelheim.

Cue Biopharma, Inc. announced a Second Amendment to its License Agreement with MIL 40G, LLC, resulting in a substantial decrease in monthly rent and an extension of the lease term.

Cue Biopharma, Inc. announced the appointment of Jill Broadfoot to its Board of Directors, the approval of a new 2025 Stock Incentive Plan, and a significant increase in authorized common stock, alongside the resignation of its Chief Financial Officer.

Cue Biopharma reported its first quarter 2025 financial results, highlighted by a strategic collaboration with Boehringer Ingelheim and a follow-on capital raise.

Cue Biopharma has announced the pricing of a public offering expected to generate approximately $20 million before deductions.

Cue Biopharma has entered into a collaboration and license agreement with Boehringer Ingelheim to develop and commercialize B cell depletion molecules, including Cue Biopharma's CUE-501 product candidate.

Cue Biopharma announced its fourth quarter and full year 2024 financial results, highlighting a strategic shift towards autoimmune programs and key leadership appointments.

Cue Biopharma announces the appointment of Pasha Sarraf to its board of directors, effective March 10, 2025.

Cue Biopharma reported encouraging Phase 1 clinical trial results for CUE-101 and CUE-102, along with a financial update for the third quarter of 2024, highlighting increased collaboration revenue and reduced operating expenses.

Cue Biopharma has successfully increased its authorized capital stock and common stock shares after a stockholder vote on October 8, 2024.

Cue Biopharma has amended its loan agreement with Silicon Valley Bank, removing a specific $20 million cash reserve requirement.

Cue Biopharma has announced a $12 million public offering of common stock and warrants to fund operations into the fourth quarter of 2025.

Michael J. Fox has resigned from Cue Biopharma's Board of Directors, effective August 28, 2024.